1. Human arylamine N-acetyltransferase 1: a drug-metabolizing enzyme and a drug target?
    Rodrigues-Lima F, Dairou J, Busi F, Dupret JM.
    Curr Drug Targets. 2010 Jun;11(6):759-66. | Pubmed
  2. Modulation of extracellular matrix/adhesion molecule expression by BRG1 is associated with increased melanoma invasiveness.
    Saladi SV, Keenen B, Marathe HG, Qi H, Chin KV, de la Serna IL.
    Mol Cancer. 2010 Oct 22;9:280. | Pubmed
  3. Protein kinase D as a potential new target for cancer therapy.
    LaValle CR, George KM, Sharlow ER, Lazo JS, Wipf P, Wang QJ.
    Biochim Biophys Acta. 2010 Dec;1806(2):183-92. | Pubmed
  4. Ferroportin and iron regulation in breast cancer progression and prognosis.
    Pinnix ZK, Miller LD, Wang W, D'Agostino R Jr, Kute T, Willingham MC, Hatcher H, Tesfay L, Sui G, Di X, Torti SV, Torti FM.
    Sci Transl Med. 2010 Aug 4;2(43):43ra56. | Pubmed
  5. Gene regulation by BCL3 in a cervical cancer cell line.
    Maldonado V, Espinosa M, Pruefer F, Patiño N, Ceballos-Canciono G, Urzua U, Juretic N, Melendez-Zajgla J.
    Folia Biol (Praha). 2010;56(4):183-93. | Pubmed
  6. SRp20 is a proto-oncogene critical for cell proliferation and tumor induction and maintenance.
    Jia R, Li C, McCoy JP, Deng CX, Zheng ZM.
    Int J Biol Sci. 2010 Dec 15;6(7):806-26. | Pubmed
  7. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers.
    Fedele CG, Ooms LM, Ho M, Vieusseux J, O'Toole SA, Millar EK, Lopez-Knowles E, Sriratana A, Gurung R, Baglietto L, Giles GG, Bailey CG, Rasko JE, Shields BJ, Price JT, Majerus PW, Sutherland RL, Tiganis T, McLean CA, Mitchell CA.
    Proc Natl Acad Sci U S A. 2010 Dec 21;107(51):22231-6. | Pubmed
  8. Prognostic value and function of KLF4 in prostate cancer: RNAa and vector-mediated overexpression identify KLF4 as an inhibitor of tumor cell growth and migration.
    Wang J, Place RF, Huang V, Wang X, Noonan EJ, Magyar CE, Huang J, Li LC.
    Cancer Res. 2010 Dec 15;70(24):fffff-91. | Pubmed
  9. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis.
    Leachman NT, Brellier F, Ferralli J, Chiquet-Ehrismann R, Tucker RP.
    Dev Growth Differ. 2010 Dec;52(9):747-55. doi: 10.1111/j.1440-169X.2010.01211.x. | Pubmed
  10. The Aurora-A/TPX2 complex: a novel oncogenic holoenzyme?
    Asteriti IA, Rensen WM, Lindon C, Lavia P, Guarguaglini G.
    Biochim Biophys Acta. 2010 Dec;1806(2):230-9. | Pubmed
  11. Aberrant overexpression of the Rgl2 Ral small GTPase-specific guanine nucleotide exchange factor promotes pancreatic cancer growth through Ral-dependent and Ral-independent mechanisms.
    Vigil D, Martin TD, Williams F, Yeh JJ, Campbell SL, Der CJ.
    J Biol Chem. 2010 Nov 5;285(45):34729-40. | Pubmed
  12. A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Zuo Z, Jones D, Yao H, Thomas DA, O'Brien S, Ravandi F, Kantarjian HM, Abruzzo LV, Medeiros LJ, Chen SS, Luthra R.
    Mod Pathol. 2010 Nov;23(11):1524-34. | Pubmed
  13. Restoration of DNA-binding and growth-suppressive activity of mutant forms of p53 via a PCAF-mediated acetylation pathway.
    Perez RE, Knights CD, Sahu G, Catania J, Kolukula VK, Stoler D, Graessmann A, Ogryzko V, Pishvaian M, Albanese C, Avantaggiati ML.
    J Cell Physiol. 2010 Nov;225(2):394-405. | Pubmed
  14. Aberrant expression of LMO4 induces centrosome amplification and mitotic spindle abnormalities in breast cancer cells.
    Montañez-Wiscovich ME, Shelton MD, Seachrist DD, Lozada KL, Johnson E, Miedler JD, Abdul-Karim FW, Visvader JE, Keri RA.
    J Pathol. 2010 Nov;222(3):271-81. | Pubmed
  15. Analysis of the Wnt/B-catenin/TCF4 pathway using SAGE, genome-wide microarray and promoter analysis: Identification of BRI3 and HSF2 as novel targets.
    Kavak E, Najafov A, Ozturk N, Seker T, Cavusoglu K, Aslan T, Duru AD, Saygili T, Hoxhaj G, Hiz MC, Unal DO, Birgül-Iyison N, Ozturk M, Koman A.
    Cell Signal. 2010 Oct;22(10):1523-35. | Pubmed
  16. Cooperation between deficiencies of IRF-4 and IRF-8 promotes both myeloid and lymphoid tumorigenesis.
    Jo SH, Schatz JH, Acquaviva J, Singh H, Ren R.
    Blood. 2010 Oct 14;116(15):2759-67. | Pubmed
  17. Reduction of Nup107 attenuates the growth factor signaling in the senescent cells.
    Kim SY, Kang HT, Choi HR, Park SC.
    Biochem Biophys Res Commun. 2010 Oct 8;401(1):131-6. | Pubmed
  18. Aurora kinase A in Barrett's carcinogenesis.
    Rugge M, Fassan M, Zaninotto G, Pizzi M, Giacomelli L, Battaglia G, Rizzetto C, Parente P, Ancona E.
    Hum Pathol. 2010 Oct;41(10):1380-6. | Pubmed
  19. HDAC3 selectively represses CREB3-mediated transcription and migration of metastatic breast cancer cells.
    Kim HC, Choi KC, Choi HK, Kang HB, Kim MJ, Lee YH, Lee OH, Lee J, Kim YJ, Jun W, Jeong JW, Yoon HG.
    Cell Mol Life Sci. 2010 Oct;67(20):3499-510. | Pubmed
  20. Prolactin receptor-integrin cross-talk mediated by SIRP(alpha) in breast cancer cells.
    Galbaugh T, Feeney YB, Clevenger CV.
    Mol Cancer Res. 2010 Oct;8(10):1413-24. | Pubmed
  21. Global levels of specific histone modifications and an epigenetic gene signature predict prostate cancer progression and development.
    Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin MA, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Tilley WD, Horsfall DJ, Ricciardelli C; Australian Prostate Cancer BioResource.
    Cancer Epidemiol Biomarkers Prev. 2010 Oct;19(10):2611-22. | Pubmed
  22. Clinical significance of Polycomb gene expression in brain tumors.
    Crea F, Hurt EM, Farrar WL.
    Mol Cancer. 2010 Sep 30;9:265. | Pubmed
  23. CD22 EXON 12 deletion as a pathogenic mechanism of human B-precursor leukemia.
    Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S.
    Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16852-7. | Pubmed
  24. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE, De Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM, Van Tilborg AA, Zwinderman AH, Geerts D, Kaspers GJ, Peter Vandertop W, Cloos J, Tannous BA, Wesseling P, Aten JA, Noske DP, Van Noorden CJ, Würdinger T.
    Cancer Cell. 2010 Sep 14;18(3):244-57. | Pubmed
  25. NBCn1 and NHE1 expression and activity in DeltaNErbB2 receptor-expressing MCF-7 breast cancer cells: contributions to pHi regulation and chemotherapy resistance.
    Lauritzen G, Jensen MB, Boedtkjer E, Dybboe R, Aalkjaer C, Nylandsted J, Pedersen SF.
    Exp Cell Res. 2010 Sep 10;316(15):2538-53. | Pubmed
  26. Kif18A is involved in human breast carcinogenesis.
    Zhang C, Zhu C, Chen H, Li L, Guo L, Jiang W, Lu SH.
    Carcinogenesis. 2010 Sep;31(9):1676-84. | Pubmed
  27. Proteomic analysis of the transitional endoplasmic reticulum in hepatocellular carcinoma: an organelle perspective on cancer.
    Roy L, Laboissière S, Abdou E, Thibault G, Hamel N, Taheri M, Boismenu D, Lanoix J, Kearney RE, Paiement J.
    Biochim Biophys Acta. 2010 Sep;1804(9):1869-81. | Pubmed
  28. Genomic profiling of adult acute lymphoblastic leukemia by single nucleotide polymorphism oligonucleotide microarray and comparison to pediatric acute lymphoblastic leukemia.
    Okamoto R, Ogawa S, Nowak D, Kawamata N, Akagi T, Kato M, Sanada M, Weiss T, Haferlach C, Dugas M, Ruckert C, Haferlach T, Koeffler HP.
    Haematologica. 2010 Sep;95(9):1481-8. | Pubmed
  29. Differentially expressed RNA from public microarray data identifies serum protein biomarkers for cross-organ transplant rejection and other conditions.
    Chen R, Sigdel TK, Li L, Kambham N, Dudley JT, Hsieh SC, Klassen RB, Chen A, Caohuu T, Morgan AA, Valantine HA, Khush KK, Sarwal MM, Butte AJ.
    PLoS Comput Biol. 2010 Sep 23;6(9). pii: efffff40. | Pubmed
  30. TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions.
    Verzi MP, Hatzis P, Sulahian R, Philips J, Schuijers J, Shin H, Freed E, Lynch JP, Dang DT, Brown M, Clevers H, Liu XS, Shivdasani RA.
    Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15157-62. | Pubmed
  31. Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery.
    Korcsmaros T, Farkas IJ, Szalay MS, Rovo P, Fazekas D, Spiro Z, Bode C, Lenti K, Vellai T, Csermely P.
    Bioinformatics. 2010 Aug 15;26(16):2042-50. | Pubmed
  32. Microarray meta-analysis database (M(2)DB): a uniformly pre-processed, quality controlled, and manually curated human clinical microarray database.
    Cheng WC, Tsai ML, Chang CW, Huang CL, Chen CR, Shu WY, Lee YS, Wang TH, Hong JH, Li CY, Hsu IC.
    BMC Bioinformatics. 2010 Aug 10;11:421. | Pubmed
  33. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation.
    Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA.
    Breast Cancer Res Treat. 2010 Aug;122(3):661-70. | Pubmed
  34. MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells.
    Chen J, Miller EM, Gallo KA.
    Oncogene. 2010 Aug 5;29(31):4399-411. | Pubmed
  35. Epithelial membrane protein-2 is a novel therapeutic target in ovarian cancer.
    Fu M, Maresh EL, Soslow RA, Alavi M, Mah V, Zhou Q, Iasonos A, Goodglick L, Gordon LK, Braun J, Wadehra M.
    Clin Cancer Res. 2010 Aug 1;16(15):3954-63. | Pubmed
  36. Chronotherapy and the molecular clock: Clinical implications in oncology.
    Innominato PF, Levi FA, Bjarnason GA.
    Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):979-1001. | Pubmed
  37. Programmed cell death 4 protein in esophageal cancer.
    Fassan M, Cagol M, Pennelli G, Rizzetto C, Giacomelli L, Battaglia G, Zaninotto G, Ancona E, Ruol A, Rugge M.
    Oncol Rep. 2010 Jul;24(1):135-9. | Pubmed
  38. Deficiency in myosin light-chain phosphorylation causes cytokinesis failure and multipolarity in cancer cells.
    Wu Q, Sahasrabudhe RM, Luo LZ, Lewis DW, Gollin SM, Saunders WS.
    Oncogene. 2010 Jul 22;29(29):4183-93. | Pubmed
  39. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, Belvin M, Friedman LS, Lackner MR.
    Clin Cancer Res. 2010 Jul 15;16(14):3670-83. | Pubmed
  40. Epigenetic regulation of vitamin D 24-hydroxylase/CYP24A1 in human prostate cancer.
    Luo W, Karpf AR, Deeb KK, Muindi JR, Morrison CD, Johnson CS, Trump DL.
    Cancer Res. 2010 Jul 15;70(14):5953-62. | Pubmed
  41. STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer.
    Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE, Saatcioglu F.
    Cancer Res. 2010 Jul 15;70(14):5818-28. | Pubmed
  42. Gene expression profiling of mouse p53-deficient epidermal carcinoma defines molecular determinants of human cancer malignancy.
    García-Escudero R, Martínez-Cruz AB, Santos M, Lorz C, Segrelles C, Garaulet G, Saiz-Ladera C, Costa C, Buitrago-Pérez A, Dueñas M, Paramio JM.
    Mol Cancer. 2010 Jul 14;9:193. | Pubmed
  43. Polycomb target genes are silenced in multiple myeloma.
    Kalushkova A, Fryknäs M, Lemaire M, Fristedt C, Agarwal P, Eriksson M, Deleu S, Atadja P, Osterborg A, Nilsson K, Vanderkerken K, Oberg F, Jernberg-Wiklund H.
    PLoS One. 2010 Jul 9;5(7):e11483. | Pubmed
  44. The phosphoinositide 3-kinase regulatory subunit p85alpha can exert tumor suppressor properties through negative regulation of growth factor signaling.
    Taniguchi CM, Winnay J, Kondo T, Bronson RT, Guimaraes AR, Alemán JO, Luo J, Stephanopoulos G, Weissleder R, Cantley LC, Kahn CR.
    Cancer Res. 2010 Jul 1;70(13):5305-15. | Pubmed
  45. Multifunctional proteins bridge mitosis with motility and cancer with inflammation and arthritis.
    Jiang J, Casalegno-Garduno R, Chen H, Schmitt A, Schmitt M, Maxwell CA.
    ScientificWorldJournal. 2010 Jun 29;10:1244-57. | Pubmed
  46. Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets.
    Qazi S, Uckun FM.
    Br J Haematol. 2010 Jun;149(6):865-73. | Pubmed
  47. Estrogen coordinates translation and transcription, revealing a role for NRSF in human breast cancer cells.
    Bronson MW, Hillenmeyer S, Park RW, Brodsky AS.
    Mol Endocrinol. 2010 Jun;24(6):1120-35. | Pubmed
  48. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
    Sheng Z, Li L, Zhu LJ, Smith TW, Demers A, Ross AH, Moser RP, Green MR.
    Nat Med. 2010 Jun;16(6):671-7. | Pubmed
  49. The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.
    El-Gazzar A, Wittinger M, Perco P, Anees M, Horvat R, Mikulits W, Grunt TW, Mayer B, Krainer M.
    Gynecol Oncol. 2010 Jun;117(3):451-9. | Pubmed
  50. Monocarboxylate transporter 1 is up-regulated in basal-like breast carcinoma.
    Pinheiro C, Albergaria A, Paredes J, Sousa B, Dufloth R, Vieira D, Schmitt F, Baltazar F.
    Histopathology. 2010 Jun;56(7):860-7. | Pubmed
  51. Ataxia telangiectasia mutated nuclear localization in head and neck cancer cells is PPP2R2B-dependent.
    Suyarnsestakorn C, Thanasupawat T, Leelahavanichkul K, Gutkind JS, Mutirangura A.
    Asian Biomedicine Vol. 4 No. 3 June 2010; 373-383.
  52. PMCA2 regulates apoptosis during mammary gland involution and predicts outcome in breast cancer.
    VanHouten J, Sullivan C, Bazinet C, Ryoo T, Camp R, Rimm DL, Chung G, Wysolmerski J.
    Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11405-10. | Pubmed
  53. The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation.
    Lian I, Kim J, Okazawa H, Zhao J, Zhao B, Yu J, Chinnaiyan A, Israel MA, Goldstein LS, Abujarour R, Ding S, Guan KL.
    Genes Dev. 2010 Jun 1;24(11):1106-18. | Pubmed
  54. The proapoptotic molecule BLID interacts with Bcl-XL and its downregulation in breast cancer correlates with poor disease-free and overall survival.
    Broustas CG, Ross JS, Yang Q, Sheehan CE, Riggins R, Noone AM, Haddad BR, Seillier-Moiseiwitsch F, Kallakury BV, Haffty BG, Clarke R, Kasid UN.
    Clin Cancer Res. 2010 Jun 1;16(11):2939-48. | Pubmed
  55. Regulation of androgen-responsive transcription by the chromatin remodeling factor CHD8.
    Menon T, Yates JA, Bochar DA.
    Mol Endocrinol. 2010 Jun;24(6):1165-74. | Pubmed
  56. Molecular mechanisms guiding embryonic mammary gland development.
    Cowin P, Wysolmerski J.
    Cold Spring Harb Perspect Biol. 2010 Jun 1;2(6):a003251. | Pubmed
  57. Differential effects of TBC1D15 and mammalian Vps39 on Rab7 activation state, lysosomal morphology, and growth factor dependence.
    Peralta ER, Martin BC, Edinger AL.
    J Biol Chem. 2010 May 28;285(22):16814-21. | Pubmed
  58. Frequent loss of heterozygosity at the interferon regulatory factor-1 gene locus in breast cancer.
    Cavalli LR, Riggins RB, Wang A, Clarke R, Haddad BR.
    Breast Cancer Res Treat. 2010 May;121(1):227-31. | Pubmed
  59. Genomic profiling of tumor initiating prostatospheres.
    Duhagon MA, Hurt EM, Sotelo-Silveira JR, Zhang X, Farrar WL.
    BMC Genomics. 2010 May 25;11:324. | Pubmed
  60. Dietary fat-dependent transcriptional architecture and copy number alterations associated with modifiers of mammary cancer metastasis.
    Gordon RR, La Merrill M, Hunter KW, Sørensen P, Threadgill DW, Pomp D.
    Clin Exp Metastasis. 2010 May;27(5):279-93. | Pubmed
  61. An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer.
    Chari R, Coe BP, Vucic EA, Lockwood WW, Lam WL.
    BMC Syst Biol. 2010 May 17;4:67. | Pubmed
  62. The role of PI 3-kinase p110beta in AKT signally, cell survival, and proliferation in human prostate cancer cells.
    Hill KM, Kalifa S, Das JR, Bhatti T, Gay M, Williams D, Taliferro-Smith L, De Marzo AM.
    Prostate. 2010 May 15;70(7):755-64. | Pubmed
  63. Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function.
    Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G.
    J Biol Chem. 2010 May 7;285(19):14160-9. | Pubmed
  64. A novel role for wnt/ca signaling in actin cytoskeleton remodeling and cell motility in prostate cancer.
    Wang Q, Symes AJ, Kane CA, Freeman A, Nariculam J, Munson P, Thrasivoulou C, Masters JR, Ahmed A.
    PLoS One. 2010 May 4;5(5):efffff. | Pubmed
  65. Extracellular matrix associated protein CYR61 is linked to prostate cancer development.
    D'Antonio KB, Toubaji A, Albadine R, Mondul AM, Platz EA, Netto GJ, Getzenberg RH.
    J Urol. 2010 Apr;183(4):1604-10. | Pubmed
  66. Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.
    Monaco ME, Creighton CJ, Lee P, Zou X, Topham MK, Stafforini DM.
    Transl Oncol. 2010 Apr;3(2):91-8. | Pubmed
  67. Epigenetic regulator MLL2 shows altered expression in cancer cell lines and tumors from human breast and colon.
    Natarajan TG, Kallakury BV, Sheehan CE, Bartlett MB, Ganesan N, Preet A, Ross JS, Fitzgerald KT.
    Cancer Cell Int. 2010 Apr 30;10:13. | Pubmed
  68. An expanded Oct4 interaction network: implications for stem cell biology, development, and disease.
    Pardo M, Lang B, Yu L, Prosser H, Bradley A, Babu MM, Choudhary J.
    Cell Stem Cell. 2010 Apr 2;6(4):382-95. | Pubmed
  69. G9a and Glp methylate lysine 373 in the tumor suppressor p53.
    Huang J, Dorsey J, Chuikov S, Pérez-Burgos L, Zhang X, Jenuwein T, Reinberg D, Berger SL.
    J Biol Chem. 2010 Mar 26;285(13):9636-41. | Pubmed
  70. Homozygous deletion of the STK11/LKB1 locus and the generation of novel fusion transcripts in cervical cancer cells.
    McCabe MT, Powell DR, Zhou W, Vertino PM.
    Cancer Genet Cytogenet. 2010 Mar;197(2):130-41. | Pubmed
  71. The ulcerative colitis marker protein WAFL interacts with accessory proteins in endocytosis.
    Pan YF, Viklund IM, Tsai HH, Pettersson S, Maruyama IN.
    Int J Biol Sci. 2010 Mar 29;6(2):163-71. | Pubmed
  72. The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells.
    Roidl A, Foo P, Wong W, Mann C, Bechtold S, Berger HJ, Streit S, Ruhe JE, Hart S, Ullrich A, Ho HK.
    Oncogene. 2010 Mar 11;29(10):1543-52. | Pubmed
  73. RPL41, a small ribosomal peptide deregulated in tumors, is essential for mitosis and centrosome integrity.
    Wang S, Huang J, He J, Wang A, Xu S, Huang SF, Xiao S.
    Neoplasia. 2010 Mar;12(3):284-93. | Pubmed
  74. Identifying common prognostic factors in genomic cancer studies: a novel index for censored outcomes.
    Rouam S, Moreau T, Broët P.
    BMC Bioinformatics. 2010 Mar 24;11:150. | Pubmed
  75. A role for fibrillar collagen deposition and the collagen internalization receptor endo180 in glioma invasion.
    Huijbers IJ, Iravani M, Popov S, Robertson D, Al-Sarraj S, Jones C, Isacke CM.
    PLoS One. 2010 Mar 22;5(3):e9808. | Pubmed
  76. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244).
    Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD.
    Cancer Res. 2010 Mar 15;70(6):2264-73. | Pubmed
  77. Transcriptomics-based identification of developmental toxicants through their interference with cardiomyocyte differentiation of embryonic stem cells.
    van Dartel DA, Pennings JL, van Schooten FJ, Piersma AH.
    Toxicol Appl Pharmacol. 2010 Mar 15;243(3):420-8. | Pubmed
  78. A novel translocation breakpoint within the BPTF gene is associated with a pre-malignant phenotype.
    Buganim Y, Goldstein I, Lipson D, Milyavsky M, Polak-Charcon S, Mardoukh C, Solomon H, Kalo E, Madar S, Brosh R, Perelman M, Navon R, Goldfinger N, Barshack I, Yakhini Z, Rotter V.
    PLoS One. 2010 Mar 11;5(3):e9657. | Pubmed
  79. HAX-1 overexpression, splicing and cellular localization in tumors.
    Trebinska A, Rembiszewska A, Ciosek K, Ptaszynski K, Rowinski S, Kupryjanczyk J, Siedlecki JA, Grzybowska EA.
    BMC Cancer. 2010 Mar 2;10:76. | Pubmed
  80. The emerging role of Krüppel-like factors in endocrine-responsive cancers of female reproductive tissues.
    Simmen RC, Pabona JM, Velarde MC, Simmons C, Rahal O, Simmen FA.
    J Endocrinol. 2010 Mar;204(3):223-31. | Pubmed
  81. | Linking the septin expression with carcinogenesis
    Liu M, Shen S, Chen F, Yu W, Yu L.
    Mol Biol Rep. 2010 Feb 27. | Pubmed
  82. Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines.
    Kadota M, Yang HH, Gomez B, Sato M, Clifford RJ, Meerzaman D, Dunn BK, Wakefield LM, Lee MP.
    PLoS One. 2010 Feb 15;5(2):e9201. | Pubmed
  83. Cytochrome P450 1B1 mRNA Untranslated Regions Interact to Inhibit Protein Translation.
    Devlin AH, Thompson P, Robson T, McKeown SR.
    Mol Carcinog. 2010 Feb;49(2):190-9. | Pubmed
  84. MYC regulation of a "poor-prognosis" metastatic cancer cell state.
    Wolfer A, Wittner BS, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S.
    Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703. | Pubmed
  85. Targets of the Tal1 transcription factor in erythrocytes: E2 ubiquitin conjugase regulation by Tal1.
    Lausen J, Pless O, Leonard F, Kuvardina ON, Koch B, Leutz A.
    J Biol Chem. 2010 Feb 19;285(8):5338-46. | Pubmed
  86. Cancer-Associated Fibroblasts Are Activated in Incipient Neoplasia to Orchestrate Tumor-Promoting Inflammation in an NF-kappaB-Dependent Manner.
    Erez N, Truitt M, Olson P, Arron ST, Hanahan D.
    Cancer Cell. 2010 Feb 17;17(2):135-47. | Pubmed
  87. Expression of interleukin-1 receptor-associated kinase-1 in non-small cell lung carcinoma and preneoplastic lesions.
    Behrens C, Feng L, Kadara H, Kim HJ, Lee JJ, Mehran R, Hong WK, Lotan R, Wistuba II.
    Clin Cancer Res. 2010 Jan 1;16(1):34-44. | Pubmed
  88. Identification of DOK genes as lung tumor suppressors.
    Berger AH, Niki M, Morotti A, Taylor BS, Socci ND, Viale A, Brennan C, Szoke J, Motoi N, Rothman PB, Teruya-Feldstein J, Gerald WL, Ladanyi M, Pandolfi PP.
    Nat Genet. 2010 Mar;42(3):216-23. Epub 2010 Feb 7. | Pubmed
  89. Quantitative proteomic profiling of prostate cancer reveals a role for miR-128 in prostate cancer.
    Khan AP, Poisson LM, Bhat VB, Fermin D, Zhao R, Kalyana-Sundaram S, Michailidis G, Nesvizhskii AI, Omenn GS, Chinnaiyan AM, Sreekumar A.
    Mol Cell Proteomics. 2010 Feb;9(2):298-312. | Pubmed
  90. Proteomics analysis of A33 immunoaffinity-purified exosomes released from the human colon tumor cell line LIM1215 reveals a tissue-specific protein signature.
    Mathivanan S, Lim JW, Tauro BJ, Ji H, Moritz RL, Simpson RJ.
    Mol Cell Proteomics. 2010 Feb;9(2):197-208. | Pubmed
  91. The potential value of microseminoprotein-beta as a prostate cancer biomarker and therapeutic target.
    Whitaker HC, Warren AY, Eeles R, Kote-Jarai Z, Neal DE.
    Prostate. 2010 Feb 15;70(3):333-40. | Pubmed
  92. Enhanced mRNA cap methylation increases cyclin D1 expression and promotes cell transformation.
    Cowling VH.
    Oncogene. 2010 Feb 11;29(6):930-6. Epub 2009 Nov 16. | Pubmed
  93. Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung.
    Yuan P, Kadara H, Behrens C, Tang X, Woods D, Solis LM, Huang J, Spinola M, Dong W, Yin G, Fujimoto J, Kim E, Xie Y, Girard L, Moran C, Hong WK, Minna JD, Wistuba II.
    PLoS One. 2010 Feb 9;5(2):e9112. | Pubmed
  94. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
    Mukasa A, Wykosky J, Ligon KL, Chin L, Cavenee WK, Furnari F.
    Proc Natl Acad Sci U S A. 2010 Feb 9;107(6):2616-21. Epub 2010 Jan 21. | Pubmed
  95. Down syndrome acute lymphoblastic leukemia, a highly heterogeneous disease in which aberrant expression of CRLF2 is associated with mutated JAK2: a report from the International BFM Study Group.
    Hertzberg L, Vendramini E, Ganmore I, Cazzaniga G, Schmitz M, Chalker J, Shiloh R, Iacobucci I, Shochat C, Zeligson S, Cario G, Stanulla M, Strehl S, Russell LJ, Harrison CJ, Bornhauser B, Yoda A, Rechavi G, Bercovich D, Borkhardt A, Kempski H, te Kronnie G, Bourquin JP, Domany E, Izraeli S.
    Blood. 2010 Feb 4;115(5):1006-17. Epub 2009 Nov 24. | Pubmed
  96. Mitotic chromosomal instability and cancer: mouse modelling of the human disease.
    Schvartzman JM, Sotillo R, Benezra R.
    Nat Rev Cancer. 2010 Feb;10(2):102-15. | Pubmed
  97. Emerging roles of deubiquitinases in cancer-associated pathways.
    Sacco JJ, Coulson JM, Clague MJ, Urbé S.
    IUBMB Life. 2010 Feb;62(2):140-57. | Pubmed
  98. A multiple-filter-multiple-wrapper approach to gene selection and microarray data classification.
    Leung Y, Hung Y.
    IEEE/ACM Trans Comput Biol Bioinform. 2010 Jan-Mar;7(1):108-17. | Pubmed
  99. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth.
    Krieg AJ, Rankin EB, Chan D, Razorenova O, Fernandez S, Giaccia AJ.
    Mol Cell Biol. 2010 Jan;30(1):344-53. | Pubmed
  100. Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer.
    Bosman JD, Yehiely F, Evans JR, Cryns VL.
    Breast Cancer Res Treat. 2010 Jan;119(1):63-70. Epub 2009 Feb 11. | Pubmed
  101. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.
    Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembelé D, Martinet N, Thibault C, Huelsken J, Brambilla E, du Manoir S.
    PLoS One. 2010 Jan 29;5(1):e8960. | Pubmed
  102. The clusterin paradigm in prostate and breast carcinogenesis.
    Rizzi F, Bettuzzi S.
    Endocr Relat Cancer. 2010 Jan 29;17(1):R1-17. | Pubmed
  103. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma.
    Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, Aldape KD, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF.
    Cancer Res. 2010 Jan 15;70(2):453-62. | Pubmed
  104. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress.
    Kim HS, Patel K, Muldoon-Jacobs K, Bisht KS, Aykin-Burns N, Pennington JD, van der Meer R, Nguyen P, Savage J, Owens KM, Vassilopoulos A, Ozden O, Park SH, Singh KK, Abdulkadir SA, Spitz DR, Deng CX, Gius D.
    Cancer Cell. 2010 Jan 19;17(1):41-52. | Pubmed
  105. RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.
    Sowalsky AG, Alt-Holland A, Shamis Y, Garlick JA, Feig LA.
    Oncogene. 2010 Jan 7;29(1):45-55. Epub 2009 Oct 5. | Pubmed
  106. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene.
    Buffa FM, Harris AL, West CM, Miller CJ.
    Br J Cancer. 2010 Jan 19;102(2):428-35. | Pubmed
  107. Nrf2 expression is regulated by epigenetic mechanisms in prostate cancer of TRAMP mice.
    Yu S, Khor TO, Cheung KL, Li W, Wu TY, Huang Y, Foster BA, Kan YW, Kong AN.
    PLoS One. 2010 Jan 5;5(1):e8579. | Pubmed
  108. Collagen and calcium-binding EGF domains 1 is frequently inactivated in ovarian cancer by aberrant promoter hypermethylation and modulates cell migration and survival.
    Barton CA, Gloss BS, Qu W, Statham AL, Hacker NF, Sutherland RL, Clark SJ, O'Brien PM.
    Br J Cancer. 2010 Jan 5;102(1):87-96. | Pubmed
  109. Gene expression analysis of macrophages that facilitate tumor invasion supports a role for Wnt-signaling in mediating their activity in primary mammary tumors.
    Ojalvo LS, Whittaker CA, Condeelis JS, Pollard JW.
    J Immunol. 2010 Jan 15;184(2):702-12. Epub 2009 Dec 16. | Pubmed
  110. Global levels of histone modifications predict prostate cancer recurrence.
    Ellinger J, Kahl P, von der Gathen J, Rogenhofer S, Heukamp LC, Gütgemann I, Walter B, Hofstädter F, Büttner R, Müller SC, Bastian PJ, von Ruecker A.
    Prostate. 2010 Jan 1;70(1):61-9. | Pubmed
  111. Functional genomic analysis of glioblastoma multiforme through short interfering RNA screening: a paradigm for therapeutic development.
    Thaker NG, Zhang F, McDonald PR, Shun TY, Lazo JS, Pollack IF.
    Neurosurg Focus. 2010 Jan;28(1):E4. | Pubmed
  112. Putative molecular signatures for the imaging of prostate cancer.
    Yang S Y, Adelstein J, Kassis AI.
    Expert Rev Mol Diagn. 2010 Jan;10(1):65-74. | Pubmed
  113. Expression of the actin-associated protein transgelin (SM22) is decreased in prostate cancer.
    Prasad PD, Stanton JA, Assinder SJ.
    Cell Tissue Res [Epub ahead of print] | Pubmed